JP2018521674A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521674A5
JP2018521674A5 JP2018504991A JP2018504991A JP2018521674A5 JP 2018521674 A5 JP2018521674 A5 JP 2018521674A5 JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018521674 A5 JP2018521674 A5 JP 2018521674A5
Authority
JP
Japan
Prior art keywords
encoding
gene
promoter
propionate
gene sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018504991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521674A (ja
Filing date
Publication date
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/037098 external-priority patent/WO2016201380A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/044922 external-priority patent/WO2017023818A1/en
Publication of JP2018521674A publication Critical patent/JP2018521674A/ja
Publication of JP2018521674A5 publication Critical patent/JP2018521674A5/ja
Pending legal-status Critical Current

Links

JP2018504991A 2015-07-31 2016-07-29 プロピオネート異化を伴う障害を治療するために操作された細菌 Pending JP2018521674A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562199445P 2015-07-31 2015-07-31
US62/199,445 2015-07-31
US201662336338P 2016-05-13 2016-05-13
USPCT/US2016/032565 2016-05-13
US62/336,338 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
US201662341320P 2016-05-25 2016-05-25
US62/341,320 2016-05-25
PCT/US2016/037098 WO2016201380A1 (en) 2015-06-10 2016-06-10 Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
USPCT/US2016/037098 2016-06-10
PCT/US2016/044922 WO2017023818A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Publications (2)

Publication Number Publication Date
JP2018521674A JP2018521674A (ja) 2018-08-09
JP2018521674A5 true JP2018521674A5 (https=) 2019-09-05

Family

ID=57944027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504991A Pending JP2018521674A (ja) 2015-07-31 2016-07-29 プロピオネート異化を伴う障害を治療するために操作された細菌

Country Status (5)

Country Link
EP (1) EP3328988A1 (https=)
JP (1) JP2018521674A (https=)
AU (1) AU2016303662A1 (https=)
CA (1) CA2996535A1 (https=)
WO (1) WO2017023818A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス,インコーポレイティド 微生物感染を防ぐための方法および組成物
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN112143689B (zh) * 2019-06-28 2023-01-03 中国科学院微生物研究所 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用
WO2021137937A2 (en) * 2019-11-05 2021-07-08 The Trustees Of Columbia University In The City Of New York Engineered bacteria containing biosensors for precision targeting and containment
CA3162277A1 (en) * 2019-12-02 2021-06-10 Astellas Pharma Inc. Ny-eso-1-containing artificial adjuvant vector cell for use in treating of cancer
AU2021208600A1 (en) * 2020-01-17 2022-07-28 Université Catholique de Louvain Genetically modified bacterium with altered envelop integrity and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston GEN NETWORKS FOR CONTROLLING GENE EXPRESSION
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
CN104024430A (zh) * 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
EP2964240B1 (en) 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides

Similar Documents

Publication Publication Date Title
JP2018521674A5 (https=)
JP2018515106A5 (https=)
Lim et al. Engineered regulatory systems modulate gene expression of human commensals in the gut
Hegarty et al. Bacteriocin production: a relatively unharnessed probiotic trait?
Bron et al. Genetic characterization of the bile salt response in Lactobacillus plantarum and analysis of responsive promoters in vitro and in situ in the gastrointestinal tract
Denou et al. Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis
Bouillaut et al. Proline-dependent regulation of Clostridium difficile Stickland metabolism
Van Pijkeren et al. Exploring optimization parameters to increase ssDNA recombineering in Lactococcus lactis and Lactobacillus reuteri
Zhao et al. Role of methionine sulfoxide reductases A and B of Enterococcus faecalis in oxidative stress and virulence
Klotz et al. S-layer associated proteins contribute to the adhesive and immunomodulatory properties of Lactobacillus acidophilus NCFM
Paul et al. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats
Fleuchot et al. Rgg-associated SHP signaling peptides mediate cross-talk in Streptococci
AU2013327059B2 (en) Immunomodulatory minicells and methods of use
JP2018504919A5 (https=)
Sun et al. Accessing the inaccessible: molecular tools for bifidobacteria
Ma et al. Global transcriptomic analysis and function identification of malolactic enzyme pathway of Lactobacillus paracasei L9 in response to bile stress
WO2014066945A1 (en) Genetically-modified probiotic for treatment of phenylketonuria
Hussain et al. Generation of lactose-and protease-positive probiotic Lacticaseibacillus rhamnosus GG by conjugation with Lactococcus lactis NCDO 712
JP2022061035A (ja) Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
Alexander et al. Exploiting prophage-mediated lysis for biotherapeutic release by Lactobacillus reuteri
Corthier et al. Use of luciferase genes as biosensors to study bacterial physiology in the digestive tract
Wang et al. Functional role of oppA encoding an oligopeptide-binding protein from Lactobacillus salivarius Ren in bile tolerance
Hays et al. Type II fatty acid synthesis pathway and cyclopropane ring formation are dispensable during Enterococcus faecalis systemic infection
Douglas et al. Directed chromosomal integration and expression of the reporter gene gusA3 in Lactobacillus acidophilus NCFM
Gaudu et al. Genetics of lactococci